BPBT
ABUS icon

Boston Private Bank & Trust’s Arbutus Biopharma ABUS Stock Holding History

Boston Private Bank & Trust’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$2K Hold
100
– – ﹤0.01% 956
2014
Q4 		$2K Hold
100
– – ﹤0.01% 1029
2014
Q3 		$2K Buy
+100
New +$1.63K ﹤0.01% 991

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Boston Private Bank & Trust's ABUS Position: Q1 2015 in Review

Boston Private Bank & Trust held its Arbutus Biopharma (ABUS) position steady in Q1 2015 at 100 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #956.

Boston Private Bank & Trust first reported a position in ABUS in Q3 2014 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold ABUS as of Q1 2015.

  • Boston Private Bank & Trust held 100 shares of Arbutus Biopharma worth $2K as of Q1 2015.
  • Boston Private Bank & Trust left its Arbutus Biopharma share count unchanged in Q1 2015.
  • Arbutus Biopharma made up ﹤0.01% of Boston Private Bank & Trust's portfolio in Q1 2015, its #956 holding.
  • Boston Private Bank & Trust first reported a position in Arbutus Biopharma in Q3 2014 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2015.

Based on Boston Private Bank & Trust's 13F filing for Q1 2015, filed 9 Apr 2015.